The New York Entrepreneur

Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Read Time:7 Second

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Americans view these Asian countries as safer now than before the pandemic
Next post McDonald’s revenue tops estimates, fueled by price hikes and overseas same-store sales growth